The difference is in the best of technologies and human resources!
Our vision is, as a technology and vaccine research and development company, to make the difference for patients in need of therapeutic or preventative vaccines.
For years, Immunor has been implementing cutting-edge technology in its R&D for developing safe vaccines for high unmet medical needs. Challenging vaccines requires dedicated strategies for the selection as well as the design of target peptide antigens. Such peptide targets are taking into consideration the specifics associated with each vaccine target as well as the genetic profile of the vaccine recipients.
Accordingly, Immunor AS is a holding company with a business idea to establish and develop early-stage technology projects. When they are ready for spin-out, these projects will be placed in separate companies and co-funded by Immunor together with new investors.